BioCentury | Jan 11, 2013
Financial News

Esanex raises $500,000 from BioCrossroads

...million in a venture round from investors that include Intersouth Partners and Lilly Ventures. Esanex's SNX-5422...
...Serenex Inc. , which Pfizer Inc. (NYSE:PFE) acquired in 2008. Pfizer gained Serenex's lead compound SNX-5422...
BioCentury | Mar 21, 2011
Product Development

Safe to move forward vs. Hsp90

...tumors (GIST) in 2009 because of high mortality. Pfizer Inc. also discontinued development of PF-04929113 (SNX-5422...
BioCentury | Nov 16, 2009
Clinical News

Astex Therapeutics preclinical data

...for >=3 days in melanoma cells. In in vivo models comparing AT13387 to 17-AAG and SNX-5422...
...is currently in Phase I testing to treat cancer. The Hsp90 inhibitors 17-AAG and SNX-5422...
BioCentury | Mar 10, 2008
Company News

Serenex, Pfizer deal

...Pfizer will acquire Serenex for an undisclosed sum. The acquisition gives Pfizer SNX-5422 , an oral...
BioCentury | Mar 10, 2008
Strategy

Hsp90 pipline

...II (HRPC), non-small cell lung cancer (NSCLC), Ph I/II (NSCLC), GIST Ph I (GIST) Serenex SNX-5422...
BioCentury | Mar 10, 2008
Finance

Ebb & Flow

...Pfizer's acquisition of oral Hsp90 company Serenex for an undisclosed amount. Pfizer (NYSE:PFE) was after SNX-5422...
BioCentury | Mar 10, 2008
Strategy

Focus pays off for Serenex

...the clinic as rapidly as possible, so we focused our resources on achieving that." Serenex's SNX-5422...
BioCentury | Mar 4, 2008
Company News

Pfizer acquiring Serenex

...Pfizer (NYSE:PFE) will acquire Serenex (Durham, N.C.) for an undisclosed amount. The acquisition gives Pfizer SNX-5422...
BioCentury | Mar 3, 2008
Clinical News

SNX-5422: Phase I start

...Phase I trial of oral SNX-5422 in 30-50 patients. Serenex Inc. , Durham, N.C. Product: SNX-5422...
BioCentury | Dec 10, 2007
Clinical News

SNX-5422: Phase I started

...trial of oral SNX-5422 in up to 50 patients. Serenex Inc. , Durham, N.C. Product: SNX-5422...
Items per page:
1 - 10 of 11